181 related articles for article (PubMed ID: 10073723)
1. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Vaccine; 1999 Feb; 17(5):454-8. PubMed ID: 10073723
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection.
Larsson C; Holmgren J; Lindahl G; Bergquist C
Infect Immun; 2004 Feb; 72(2):1184-7. PubMed ID: 14742572
[TBL] [Abstract][Full Text] [Related]
3. Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Infect Immun; 1996 Sep; 64(9):3518-23. PubMed ID: 8751893
[TBL] [Abstract][Full Text] [Related]
4. Cross-protection between group A and group B streptococci due to cross-reacting surface proteins.
Stâlhammar-Carlemalm M; Areschoug T; Larsson C; Lindahl G
J Infect Dis; 2000 Jul; 182(1):142-9. PubMed ID: 10882591
[TBL] [Abstract][Full Text] [Related]
5. Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections.
Stålhammar-Carlemalm M; Stenberg L; Lindahl G
J Exp Med; 1993 Jun; 177(6):1593-603. PubMed ID: 8496678
[TBL] [Abstract][Full Text] [Related]
6. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Gravekamp C; Kasper DL; Paoletti LC; Madoff LC
Infect Immun; 1999 May; 67(5):2491-6. PubMed ID: 10225912
[TBL] [Abstract][Full Text] [Related]
7. Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V.
Areschoug T; Stålhammar-Carlemalm M; Larsson C; Lindahl G
Infect Immun; 1999 Dec; 67(12):6350-7. PubMed ID: 10569749
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with highly purified cell surface proteins confers protection against experimental group B streptococcal infection.
Larsson C; Stålhammar-Carlemalm M; Lindahl G
Adv Exp Med Biol; 1997; 418():851-3. PubMed ID: 9331786
[No Abstract] [Full Text] [Related]
9. Nonimmunodominant regions are effective as building blocks in a streptococcal fusion protein vaccine.
Stålhammar-Carlemalm M; Waldemarsson J; Johnsson E; Areschoug T; Lindahl G
Cell Host Microbe; 2007 Dec; 2(6):427-34. PubMed ID: 18078694
[TBL] [Abstract][Full Text] [Related]
10. Association between low concentrations of antibodies to protein alpha and Rib and invasive neonatal group B streptococcal infection.
Larsson C; Lindroth M; Nordin P; Stålhammar-Carlemalm M; Lindahl G; Krantz I
Arch Dis Child Fetal Neonatal Ed; 2006 Nov; 91(6):F403-8. PubMed ID: 17056838
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity.
Seepersaud R; Hanniffy SB; Mayne P; Sizer P; Le Page R; Wells JM
Infect Immun; 2005 Mar; 73(3):1671-83. PubMed ID: 15731068
[TBL] [Abstract][Full Text] [Related]
12. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
[TBL] [Abstract][Full Text] [Related]
13. Development of experimental GBS vaccine for mucosal immunization.
Gupalova T; Leontieva G; Kramskaya T; Grabovskaya K; Bormotova E; Korjevski D; Suvorov A
PLoS One; 2018; 13(5):e0196564. PubMed ID: 29727446
[TBL] [Abstract][Full Text] [Related]
14. Immunization with a recombinant BibA surface protein confers immunity and protects mice against group B Streptococcus (GBS) vaginal colonization.
Dos Santos NFB; da Silva LR; Costa FJMD; de Mattos DM; de Carvalho E; Ferreira LCS; Ferreira RCC
Vaccine; 2020 Jul; 38(33):5286-5296. PubMed ID: 32571719
[TBL] [Abstract][Full Text] [Related]
15. Group B Streptococcus: developing a correlate of protection for a vaccine against neonatal infections.
Dangor Z; Lala SG; Kwatra G; Madhi SA
Curr Opin Infect Dis; 2016 Jun; 29(3):262-7. PubMed ID: 26926474
[TBL] [Abstract][Full Text] [Related]
16. Temperature-Induced Self-Assembly of the Group B Streptococcus (GBS) Fusion Antigen GBS-NN.
Rose F; Roovers S; Fano M; Harloff-Helleberg S; Kirkensgaard JJK; Hejnaes K; Fischer P; Foged C
Mol Pharm; 2018 Jul; 15(7):2584-2593. PubMed ID: 29745668
[TBL] [Abstract][Full Text] [Related]
17. Vaccination With a Latch Peptide Provides Serotype-Independent Protection Against Group B Streptococcus Infection in Mice.
Lin SM; Jang AY; Zhi Y; Gao S; Lim S; Lim JH; Song JY; Sullam PM; Rhee JH; Seo HS
J Infect Dis; 2017 Dec; 217(1):93-102. PubMed ID: 29106586
[TBL] [Abstract][Full Text] [Related]
18. Recombinant group B Streptococcus alpha-like protein 3 is an effective immunogen and carrier protein.
Yang HH; Mascuch SJ; Madoff LC; Paoletti LC
Clin Vaccine Immunol; 2008 Jul; 15(7):1035-41. PubMed ID: 18463225
[TBL] [Abstract][Full Text] [Related]
19. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
20. Oral vaccine based on a surface immunogenic protein mixed with alum promotes a decrease in Streptococcus agalactiae vaginal colonization in a mouse model.
Diaz-Dinamarca DA; Soto DA; Leyton YY; Altamirano-Lagos MJ; Avendaño MJ; Kalergis AM; Vasquez AE
Mol Immunol; 2018 Nov; 103():63-70. PubMed ID: 30205305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
